Table 3 Patients characteristics of 7 included studies
From: Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis
Study, year | Design | Age (years) T/C | Male T/C | HF T/C | HTN T/C | CAD T/C | HbA1c (%) T/C | β-blocker T/C | CCB T/C | ACEI/ARB T/C | Statin T/C | Insulin T/C |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
PROactive, 2005 [12] | RCT | 61.9/61.6 | 67%/66% | NA | 75%/76% | 48%/48% | 7.8/7.9 | 55%/54% | 34%/37% | 70%/70% | 43%/43% | 33.2%/34% |
Anglade, 2007 [13] | Nested case control study of patients from the AFIST I, II and III trials | 65.8/67.2 | 72.5%/71.5% | 15.0%/18.8% | 90.0%/75.7% | NA | NA | 75.0%/75.0% | 12.5%/21.5% | 75.0%/56.9% | 77.5%/61.8% | NA |
RECORD, 2009 [14] | RCT | 58.4/58.5 | 51.4%/51.7% | 0.5%/0.4% | NA | NA | 7.9/7.9 | 22.6%/20.9% | 19.1%/21.6% | 43.1%/42.1% | 18%/19.2% | NA |
Gu, 2011 | Prospective cohort study | 59.6/58.7 | 52.9%/45.5% | 0/0 | 62.7%/72.7% | 5.9%/5.1% | 6.2/6.4 | 35.3%/37.4% | 35.3%/28.3% | 56.9%/45.5% | 13.7%/12.1% | 3.9%/2.0% |
Chao, 2012 [16] | Nested case control study of patients from NHIRD | 53.7/54.1 | 52.9%/53.6% | 4.1%/4.7% | 38.1%/44.5% | 16.9%/18.4% | NA | 45.5%/46.4% | NA | 68.6%/68.3% | 59%/57.4% | 0/0 |
Liu, 2014 [17] | RCT | 60.70/62.25 | 74.3%/ 65.8% | 0/0 | 28.6%/30.3% | 28.6%/30.3% | 6.41/6.19 | 41.4%/38.2% | 20%/17.1% | NA | 31.4%/34.2% | NA |
Pallisgaard, 2016 [18] | Prospective cohort study | 59.59/62.40 | 56.7%/ 58.1% | 2.3%/4.9% | 50.2%/48.4% | NA | NA | 31.5%/31.5% | NA | 58.8%/55.9% | 58.0%/53.0% | NA |